1. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373(9674):1550-1561. doi:10.1016/S0140-6736(09)60237-3
2. Vaidya T, Menzer C, Ponce DM, Markova A. Inpatient management of mucocutaneous GVHD. Curr Dermatol Rep. 2019;8(4):258-278. doi:10. 1007/s13671-019-00280-3
3. Beres AJ, Drobyski WR. The role of regulatory T cells in the biology of graft versus host disease. Front Immunol. 2013;4:163. doi:10.3389/fimmu. 2013.00163
4. Smith Knutsson E, Nicklasson M, Björk Y, Stenberg K, Sundfeldt K, Brune M. Late follow-up of genital and ophthalmologic chronic graft-vs-host disease in females after allogeneic stem cell transplantation. Acta Obstet Gynecol Scand. 2022;101(3):364-373. doi: 10.1111/aogs.14308
5. Corson SL, Sullivan K, Batzer F, August C, Storb R, Thomas ED. Gynecologic manifestations of chronic graft-versus-host disease. Obstet Gynecol. 1982;60(4):488-492. doi.org/10.1017/CBO9780511576751.020
6. Spinelli S, Chiodi S, Costantini S, et al. Female genital tract graft-versus-host disease following allogeneic bone marrow transplantation. Haematologica. 2003;88(10):1163-1168.
7. Machado AMN, Hamerschlak N, Rodrigues M, Piccinato CA, Podgaec S, Mauad LMQ. Female genital tract chronic graft-versus-host disease: a narrative review. Hematol Transfus Cell Ther. 2019;41(1):69-75. doi:10. 1016/j.htct.2018.06.005
8. Stratton P, Turner ML, Childs R, et al. Vulvovaginal chronic graft-versus-host disease with allogeneic hematopoietic stem cell transplantation. Obstet Gynecol. 2007;110(5):1041-1049. doi:10.1097/01.AOG.0000285998.75450.86
9. Zantomio D, Grigg AP, MacGregor L, Panek-Hudson Y, Szer J, Ayton R. Female genital tract graft-versus-host disease: incidence, risk factors and recommendations for management. Bone Marrow Transplant. 2006;38(8):567-572. doi:10.1038/sj.bmt.1705487
10. Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood. 2002;100(2):415-419. doi:10.1182/blood-2002- 01-0011
11. Couriel D, Carpenter PA, Cutler C, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease V. Biol Blood Marrow Transplant. 2006;12(4):375-396. doi:10.1016/j.bbmt.2006.02.003
12. Cizek SM, El-Bietar J, Rubinstein J, et al. Pediatric and young adult vulvovaginal graft-versus-host disease. Biol Blood Marrow Transplant. 2019;25(12):2408-2415. doi:10.1016/j.bbmt.2019.07.015
13. Kornik RI, Rustagi AS. Vulvovaginal graft-versus-host disease. Obstet Gynecol Clin North Am. 2017;44(3):475-492. doi:10.1016/j.ogc.2017.05. 007
14. Hirsch P, Leclerc M, Rybojad M, et al. Female genital chronic graft-versus-host disease: importance of early diagnosis to avoid severe complications. Transplantation. 2012;93(12):1265-1269. doi:10.1097/TP. 0b013e31824f3dcd
15. Spiryda LB, Laufer MR, Soiffer RJ, Antin JA. Graft-versus-host disease of the vulva and/or vagina: diagnosis and treatment.Biol Blood Marrow Transplant. 2003;9(12):760-765. doi:10.1016/j.bbmt.2003.08.001